Last reviewed · How we verify
NCT02825784: Renastart
A Multicenter Study to Evaluate the Nutritional Suitability of Renastart
NA trial testing Renastart in Chronic Kidney Disease in 12 participants. Completed in 31 October 2019.
31 May 2019
Quick facts
| Lead sponsor | Vitaflo International, Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 6 January 2017 |
| Primary completion | 31 May 2019 |
| Estimated completion | 31 October 2019 |
| Sites | 3 locations across Germany |
Drugs / interventions tested
- Renastart
Conditions studied
- Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
- Hyperkalemia — all drugs for Hyperkalemia →
Sponsor
Vitaflo International, Ltd
Who can join
Under 10, any sex, with Chronic Kidney Disease or Hyperkalemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02825784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease
Currently open trials in the same condition.
- NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
- NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
- NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
Other Vitaflo International, Ltd trials
Trials by the same sponsor.
- NCT05995717 — Evaluation of PKU UP · NA · active not recruiting
- NCT04898829 — Evaluation of PKU Explore France · NA · completed
- NCT04761588 — Evaluation of TYR Sphere in France · NA · completed
- NCT05096988 — Evaluation of PKU Sphere Liquid · NA · completed
- NCT05051657 — Evaluation of the Express Plus Range · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02825784 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vitaflo International, Ltd
- Last refreshed: 16 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02825784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing